Major locus influencing plasma APO-A1 levels also controls plasma HDL3-C concentrations

Related Experiment Video

Updated: Oct 29, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

G Livshits1, M Vainder, M Blettner

  • 1Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Israel. gregl@ccsg.tau.ac.il

Genetic Epidemiology
|May 21, 1998
PubMed

Insights

Apolipoprotein A1 (APO-A1) major locus significantly influences high-density lipoprotein cholesterol (HDL-C) levels, particularly HDL3-C. This finding supports a key genetic link between APO-A1 and HDL3-C, impacting cardiovascular health.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Biochemistry

Background:

  • Elevated apolipoprotein A1 (APO-A1) and high-density lipoprotein cholesterol (HDL-C) are crucial protective factors against atherosclerosis and coronary heart disease.
  • Understanding the genetic underpinnings of these lipid levels is vital for developing targeted interventions.

Purpose of the Study:

  • To investigate whether a major genetic locus influencing apolipoprotein A1 (APO-A1) plasma levels also controls variations in HDL3-C and HDL2-C levels.
  • To determine the genetic relationship between APO-A1 and HDL-C subfractions.

Main Methods:

  • Utilized data from 970 Israeli individuals across 228 pedigrees.
  • Applied univariate and bivariate complex segregation analyses using MAN-3 and PAP-4.0 statistical packages.
  • Tested hypotheses regarding major gene involvement and pleiotropic effects.

Main Results:

  • Strong evidence supports a major gene locus for APO-A1 that also determines HDL3-C variation.
  • Environmental and sporadic models were rejected (P < 0.001) in bivariate analysis.
  • The pleiotropic effect of the APO-A1 locus on HDL3-C transmission was confirmed (P < 0.001), with a bivariate Mendelian model accepted (P > 0.05).
  • Results for APO-A1's effect on HDL2-C were inconclusive, suggesting possible minor genetic covariation.

Conclusions:

  • A major genetic locus significantly influences both APO-A1 and HDL3-C plasma concentrations, indicating a strong genetic link.
  • This locus plays a critical role in the genetic determination of HDL3-C levels.
  • The genetic control of HDL2-C by the APO-A1 locus remains unclear, warranting further investigation.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...